ERBB2 and breast carcinoma: A randomized phase 2 trial (KATE2) did not show PFS advantage in previously treated metastatic HER2+ breast cancer who received atezolizumab + T-DM1 vs. T-DM1+ placebo: 8.2 months vs. 6.8 months (HR 0.82, p = 0.33) [54].